1-20 of 23
Antonio Jimeno
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors

Free
Elaine T. Lam, S. Gail Eckhardt, Wells Messersmith, Antonio Jimeno, Cindy L. O'Bryant, Ramesh K. Ramanathan, Glen J. Weiss, Manpreet Chadha, Abbie Oey, Han Ting Ding, Patricia A. Culp, Stephan F. Keller, Vivian Y. Zhao, L. Claire Tsao, Anil Singhal, Kyle D. Holen, Daniel Von Hoff
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1): 215–221.
https://doi.org/10.1158/1535-7163.MCT-17-0330
Published: 01 January 2018
View articletitled, Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors in another window
Journal Articles

Abstract B79: A first-in-human Phase 1 study of anti-cancer stem cell (CSC) agent OMP-54F28 (FZD8-Fc) targeting the WNT pathway in patients with advanced solid tumors.

Free
David C. Smith, Michael Gordon, Wells Messersmith, Rashmi Chugh, David Mendelson, Jakob Dupont, Robert Stagg, Ann M. Kapoun, Lu Xu, Rainer K. Brachmann, Antonio Jimeno
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B79.
https://doi.org/10.1158/1535-7163.TARG-13-B79
Published: 01 November 2013
View articletitled, Abstract B79: A first-in-human Phase 1 study of anti-cancer stem cell (CSC) agent OMP-54F28 (FZD8-Fc) targeting the WNT pathway in patients with advanced solid tumors.
Journal Articles

Abstract B268: A Phase I Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with intermediate/high risk locally advanced squamous cell carcinoma of the head and neck.

Free
Antonio Jimeno, Thomas Galloway, Lori Wirth, Jill Gilbert, Nabil Saba, Julie Bauman, Dimitrios Colevas, Ranee Mehra, David Raben, Cheng-Jung Lai, Robert Laliberte, Maurizio Voi, Barbara Burtness
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B268.
https://doi.org/10.1158/1535-7163.TARG-13-B268
Published: 01 November 2013
View articletitled, Abstract B268: A Phase I Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with intermediate/high risk locally advanced squamous cell carcinoma of the head and neck.
Journal Articles

The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas

Free
Ryan T. Anderson, Stephen B. Keysar, Daniel W. Bowles, Magdalena J. Glogowska, David P. Astling, J. Jason Morton, Phuong Le, Adrian Umpierrez, Justin Eagles-Soukup, Gregory N. Gan, Brian W. Vogler, Daniel Sehrt, Sarah M. Takimoto, Dara L. Aisner, Francois Wilhelm, Barbara A. Frederick, Marileila Varella-Garcia, Aik-Choon Tan, Antonio Jimeno
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (10): 1994–2005.
https://doi.org/10.1158/1535-7163.MCT-13-0206
Published: 07 October 2013
View articletitled, The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas
Open the PDF for The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas in another window
Includes: Supplementary data
Journal Articles

Abstract C18: A phase I study of enavatuzumab (PDL192, ABT-361), a first-in-class human monoclonal antibody targeting TWEAK (tumor necrosis factor-like inducer of apoptosis) receptor, in patients (Pts) with advanced solid tumors.

Free
Elaine T. Lam, S. Gail Eckhardt, Wells Messersmith, Antonio Jimeno, Cindy L. O'Bryant, Ramesh K. Ramanathan, Glen J. Weiss, Manpreet Chadha, Monica Fulk, Ranay Yarian, Abbie Oey, Han Ting Ding, Patricia Culp, Teresa Parli, Claire Tsao, Anil Singhal, Mihail Obrocea, Kyle D. Holen, Daniel Von Hoff
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C18.
https://doi.org/10.1158/1535-7163.TARG-11-C18
Published: 12 November 2011
View articletitled, Abstract C18: A phase I study of enavatuzumab (PDL192, ABT-361), a first-in-class human monoclonal antibody targeting TWEAK (tumor necrosis factor-like inducer of apoptosis) receptor, in patients (Pts) with advanced solid tumors.
Journal Articles

Abstract A170: Results from the phase 1 portion of a phase 1/2 study of the irreversible PI-3K inhibitor PX-866 and docetaxel.

Free
Antonio Jimeno, Neil Senzer, Wen Wee Ma, Charles Rudin, Daniel Bowles, Alex Vo, Scott Peterson, Diana Hausman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A170.
https://doi.org/10.1158/1535-7163.TARG-11-A170
Published: 12 November 2011
View articletitled, Abstract A170: Results from the phase 1 portion of a phase 1/2 study of the irreversible PI-3K inhibitor PX-866 and docetaxel.
Journal Articles

Abstract A174: Results from the phase 1 portion of a phase 1/2 study of the irreversible PI-3K inhibitor PX-866 and cetuximab.

Free
Neil Senzer, Daniel Bowles, Roger B. Cohen, Alex Vo, Kevin Klucher, Scott Peterson, Diana F. Hausman, Antonio Jimeno
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A174.
https://doi.org/10.1158/1535-7163.TARG-11-A174
Published: 12 November 2011
View articletitled, Abstract A174: Results from the phase 1 portion of a phase 1/2 study of the irreversible PI-3K inhibitor PX-866 and cetuximab.
Journal Articles

More than Markers: Biological Significance of Cancer Stem Cell-Defining Molecules

Free
Stephen B. Keysar, Antonio Jimeno
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (9): 2450–2457.
https://doi.org/10.1158/1535-7163.MCT-10-0530
Published: 08 September 2010
View articletitled, More than Markers: Biological Significance of Cancer Stem Cell-Defining Molecules
Open the PDF for More than Markers: Biological Significance of Cancer Stem Cell-Defining Molecules in another window
Journal Articles

A Fine-Needle Aspirate–Based Vulnerability Assay Identifies Polo-Like Kinase 1 as a Mediator of Gemcitabine Resistance in Pancreatic Cancer

Free
Antonio Jimeno, Belen Rubio-Viqueira, N.V. Rajeshkumar, Audrey Chan, Anna Solomon, Manuel Hidalgo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (2): 311–318.
https://doi.org/10.1158/1535-7163.MCT-09-0693
Published: 09 February 2010
View articletitled, A Fine-Needle Aspirate–Based Vulnerability Assay Identifies Polo-Like Kinase 1 as a Mediator of Gemcitabine Resistance in Pancreatic Cancer
Open the PDF for A Fine-Needle Aspirate–Based Vulnerability Assay Identifies Polo-Like Kinase 1 as a Mediator of Gemcitabine Resistance in Pancreatic Cancer in another window
Journal Articles

Abstract B238: A phase 1 study of belinostat (PXD101) in combination with bortezomib in patients with advanced solid tumors or lymphoma

Free
Sujatha Nallapareddy, Stephen Leong, Ross Camidge, Lia Gore, Sami Diab, Wells Messersmith, Karl Lewis, Colin Weekes, Daniel Gustafson, Antonio Jimeno, James Zwiebel, Igor Espinoza‐Delgado, Gail Eckhardt, Cindy O'Bryant
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B238.
https://doi.org/10.1158/1535-7163.TARG-09-B238
Published: 10 December 2009
View articletitled, Abstract B238: A phase 1 study of belinostat (PXD101) in combination with bortezomib in patients with advanced solid tumors or lymphoma
Journal Articles

Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts

Free
Wells A. Messersmith, N.V. Rajeshkumar, Aik Choon Tan, Xiao Fei Wang, Veronica Diesl, Sung E. Choe, Max Follettie, Christina Coughlin, Frank Boschelli, Elena Garcia-Garcia, Fernando Lopez-Rios, Antonio Jimeno, Manuel Hidalgo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (6): 1484–1493.
https://doi.org/10.1158/1535-7163.MCT-09-0075
Published: 10 June 2009
View articletitled, Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts
Open the PDF for Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts in another window
Includes: Supplementary data
Journal Articles

A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development

Free
Antonio Jimeno, Georg Feldmann, Ana Suárez-Gauthier, Zeshaan Rasheed, Anna Solomon, Gang-Ming Zou, Belen Rubio-Viqueira, Elena García-García, Fernando López-Ríos, William Matsui, Anirban Maitra, Manuel Hidalgo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (2): 310–314.
https://doi.org/10.1158/1535-7163.MCT-08-0924
Published: 11 February 2009
View articletitled, A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development
Open the PDF for A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development in another window
Journal Articles

Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer

Free
Dongweon Song, Raghothama Chaerkady, Aik Choon Tan, Elena García-García, Anuradha Nalli, Ana Suárez-Gauthier, Fernando López-Ríos, Xian Feng Zhang, Anna Solomon, Jeffrey Tong, Margaret Read, Christian Fritz, Antonio Jimeno, Akhilesh Pandey, Manuel Hidalgo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (10): 3275–3284.
https://doi.org/10.1158/1535-7163.MCT-08-0508
Published: 13 October 2008
View articletitled, Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer
Open the PDF for Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer in another window
Includes: Supplementary data
Journal Articles

Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a small molecule inhibitor of Src/Abl, in human pancreatic tumor xenografts

Free
N.V Rajeshkumar, Antonio Jimeno, XiaoFei Wang, Anna Solomon, Elena Garcia-Garcia, Fernando Lopez-Rios, Veronica Diesel, Sung Choe, Max Follettie, Christina Coughlin, Frank Boschelli, Wells Messersmith, Manuel Hidalgo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A250.
Published: 01 November 2007
View articletitled, Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a small molecule inhibitor of Src/Abl, in human pancreatic tumor xenografts
Journal Articles

Coordinated over-expression of genes in the EGFR pathway predicts sensitivity to EGFR inhibition in pancreatic cancer

Free
Antonio Jimeno, Aik Choon Tan, Jordy Coffa, N V Rajeshkumar, Peter Kulesza, Belen Rubio-Viqueira, Jenna Wheelhouse, Begona Diosdadp, Wells Messersmith, Christine Iacobuzio-Donahue, Anirban Maitra, Marileila Varela-Garcia, Fred Hirsch, Manuel Hidalgo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B108.
Published: 01 November 2007
View articletitled, Coordinated over-expression of genes in the EGFR pathway predicts sensitivity to EGFR inhibition in pancreatic cancer
Journal Articles

Design, synthesis and evaluation of microtubule inhibitors phenoxy pyridine (PP) and phenyl sulfanyl pyridine (PSP) analogs for cancer therapy

Free
Ravi Anchoori, Madeleine Kortenhorst, Antonio Jimeno, Taradas Sarkar, Gurulingappa Hallur, P.J Diest, Manuel Hidalgo, Ernest Hamel, Saeed Khan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B277.
Published: 01 November 2007
View articletitled, Design, synthesis and evaluation of microtubule inhibitors phenoxy pyridine (PP) and phenyl sulfanyl pyridine (PSP) analogs for cancer therapy
Journal Articles

CXCR4 activation mediates resistance to mTOR-directed therapy via regulation of VHL

Free
Colin Weekes, Dongweon Song, Belen Rubio-Viqueira, Antonio Jimeno, Wells Messersmith, Gail Eckhardt, Manuel Hidalgo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A197.
Published: 01 November 2007
View articletitled, CXCR4 activation mediates resistance to mTOR-directed therapy via regulation of VHL
Journal Articles

Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer

Free
Antonio Jimeno, Gurulingappa Hallur, Audrey Chan, Xiangfeng Zhang, George Cusatis, Fonda Chan, Preeti Shah, Rongbing Chen, Ernest Hamel, Elizabeth Garrett-Mayer, Saeed Khan, Manuel Hidalgo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (5): 1509–1516.
https://doi.org/10.1158/1535-7163.MCT-06-0592
Published: 18 May 2007
View articletitled, Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer
Open the PDF for Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer in another window
Journal Articles

Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer

Free
Antonio Jimeno, Belen Rubio-Viqueira, Maria L. Amador, Victor Grunwald, Anirban Maitra, Christine Iacobuzio-Donahue, Manuel Hidalgo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (3): 1079–1088.
https://doi.org/10.1158/1535-7163.MCT-06-0448
Published: 15 March 2007
View articletitled, Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer
Open the PDF for Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer in another window
Journal Articles

Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays

Free
Belen Rubio-Viqueira, Heather Mezzadra, Matthew E. Nielsen, Antonio Jimeno, Xianfeng Zhang, Christine Iacobuzio-Donahue, Anirban Maitra, Manuel Hidalgo, Soner Altiok
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (2): 515–523.
https://doi.org/10.1158/1535-7163.MCT-06-0388
Published: 16 February 2007
View articletitled, Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays
Open the PDF for Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays in another window